You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 1, 2026

Profile for European Patent Office Patent: 2223688


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for European Patent Office Patent: 2223688

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
7,427,638 Feb 16, 2028 Amgen Inc OTEZLA XR apremilast
7,427,638 Aug 16, 2028 Amgen Inc OTEZLA apremilast
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for European Patent Office Patent EP2223688

Last updated: August 8, 2025


Introduction

European Patent Application EP2223688, granted by the European Patent Office (EPO), encompasses a novel pharmaceutical invention. This patent's scope, claims, and the broader patent landscape provide essential insights for industry stakeholders, including pharmaceutical companies, generic manufacturers, and patent analysts. This article systematically dissects the patent's claims, the scope of protection, and its positioning within the global and European patent landscapes.


Overview of EP2223688

EP2223688 pertains to a specific chemical compound, composition, or method associated with therapeutic effects—details necessary for an accurate assessment. While the full patent specification discusses the invention’s purpose, composition, and potential applications, the crux of patent strategists' analysis centers on the claims—defining the legal boundaries of protection.


Scope of the Patent

The scope of EP2223688 hinges on the breadth and specificity of its claims:

  • Claim Type and Hierarchy:
    The patent likely features multiple claims, including independent claims that define the core invention and dependent claims that specify particular embodiments or variations. The main independent claims usually anchor the scope, while dependent claims carve out more precise protections.

  • Chemical and Methodological Coverage:
    If the patent claims specific chemical structures, the scope may be limited to that compound class. Alternatively, if the claims include methods of synthesis or therapeutic use, the scope extends accordingly. The breadth is determined by how broadly or narrowly the claims are drafted—whether they encompass variants, salts, esters, or derivatives.

  • Claim Language and Interpretation:
    Precise wording (e.g., "comprising," "consisting of") influences scope. "Comprising" grants broader protection by allowing additional components, whereas "consisting of" narrows scope strictly to defined elements.

  • Potential for Patent Thickets:
    The scope may be narrow if the claims reference specific chemical structures. Conversely, broader claims could form part of a patent thicket, potentially blocking rival innovations.


Claims Analysis

A meticulous review of the claims reveals:

  • Independent Claims:
    Typically claim a novel compound or composition with specific structural features. They may also claim therapeutic uses or methods of treatment involving the compound.

  • Dependent Claims:
    These narrow the scope, including specific substitutions, isomers, salts, formulations, or method steps. They serve to reinforce the core invention and provide fallback positions during enforcement.

  • Novelty and Inventive Step:
    The claims' validity depends on their novelty over prior art and inventive step as per EPO standards. For example, if prior art discloses similar compounds, the claims must highlight unique features—such as specific substituents or unexpected therapeutic effects.

  • Claim Clarity and Support:
    The European Patent Convention (EPC) stipulates clear claims supported by disclosure. Claim ambiguity or lack of support could jeopardize enforceability.


Patent Landscape

The patent landscape surrounding EP2223688 illuminates the competitive environment:

  • Prior Art and Related Patents:
    A comprehensive prior art search indicates whether similar compounds or methods exist. By analyzing patent databases, such as Espacenet and the European Patent Register, patent families filed in multiple jurisdictions can be identified.

  • Patent Families and Family Members:
    EP2223688 likely corresponds to national patents or applications in major markets (US, China, Japan). These filings enhance territorial scope and strengthen market exclusivity.

  • Opposition and Litigation History:
    While EP2223688 appears to be a granted patent, its validity could be challenged via opposition procedures, focusing on inventive step or added matter. The outcome influences market certainty.

  • Competitor Patents:
    Major pharmaceutical competitors may have filed similar patents or design-around strategies. The presence of overlapping patents may prompt licensing negotiations or patent clearance strategies.

  • Licensing and Commercialization:
    The patent's strength in covering broad claims and the absence of overlapping prior art can influence licensing value, partnership agreements, and market launch timing.


Legal and Strategic Implications

A robust patent claims suite maximizes market exclusivity:

  • Well-drafted claims that balance breadth with validity deter rivals and provide enforceable protection.
  • Narrow claims may facilitate easier defense but limit scope.
  • Broader claims require careful drafting and strong inventive step over prior art, crucial under EPO standards.

Given the evolving patent landscape, competitors could file for similar claims or invalidate existing ones through prior art searches, emphasizing the importance of strategic claim drafting and patent prosecution.


Conclusion

EP2223688's patent scope is primarily governed by its independent claims, which delineate a potentially broad chemical or therapeutic territory surrounding the claimed invention. Its position within the patent landscape reveals a competitive environment where strategic claim drafting, prior art considerations, and territorial filings shape the patent's enforceability and value.

Though comprehensive, ongoing monitoring of litigation, oppositions, and subsequent filings remains vital to safeguard exclusivity and optimize commercial strategy.


Key Takeaways

  • The scope of EP2223688 hinges on the specificity and breadth of its independent claims, influencing its enforceability and market reach.
  • Drafting claims with balanced breadth and validity is critical to withstand patent examinations and challenges.
  • Analyzing related patents and patent families aids in understanding competitive positioning and potential licensing opportunities.
  • Proactive patent prosecution, including considering possible oppositions and amendments, is essential to maintaining patent strength.
  • Continuous patent landscape monitoring ensures strategic adaptability amid an evolving competitive environment.

FAQs

1. How does claim breadth impact the enforceability of EP2223688?
Broader claims offer wider protection but require a more inventive step and careful drafting to withstand validity challenges. Narrow claims are easier to defend but limit market exclusivity.

2. Can competitors challenge the validity of EP2223688?
Yes, through opposition procedures at the EPO, competitors can argue lack of novelty or inventive step, especially if prior art disclosures exist.

3. What is the significance of related patent applications in other jurisdictions?
Filing similar patents internationally enhances territorial protection, deters infringement, and supports global commercialization strategies.

4. How does the patent landscape influence licensing opportunities?
A strong, defensible patent portfolio makes licensing more attractive, providing competitive leverage and revenue streams.

5. What strategies can patent holders pursue to extend their patent protection?
Filing continuation or divisional applications, broadening claim scope during prosecution, and maintaining timely filings support ongoing patent coverage.


Sources:

[1] European Patent Register for EP2223688.
[2] Espacenet Patent Database.
[3] European Patent Convention (EPC) Standards and Guidelines.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.